[2 In 2 Out]This audio interface has 2 high-headroom instrument inputs and 2 out USB-C audio interfaces with a high-headroom, Class A DYNA microphone preamplifier, giving your vocal recordings a ...

Our tried and tested pick of USB and Thunderbolt interfaces for Mac and PC across every budget, plus full reviews, in-depth testing, and buying advice If you’re looking for the best audio interface ...

Lexicon Audio System £1,010, Convenience Pack+ second row Comfort Seat Pack including heated steering wheel, rear laminated side glass, heated front and rear seats, rear air conditioning with auto ...

Traditionally, my living room has been loaded from top to bottom with different audio equipment. There’s a Sonos Era 300 in the corner for Spatial Audio duties; a soundbar nestled under my TV ...

Viatris is ponying up $25 million upfront to obtain the rights to sell Lexicon Pharmaceuticals’ SGLT1/SGLT2 heart med sotagliflozin, known commercially as Inpefa, in all global markets beyond ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), with a price target of $10.00. The company’s shares ...

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), retaining the price target of $10.00. Joseph Pantginis has given his Buy ...

The partnership is set to capitalise on Viatris’ extensive global reach and expertise in the cardiovascular sector. Credit: Jo Panuwat D/Shutterstock. Lexicon Pharmaceuticals has entered a licensing ...

The deal is a boost to Lexicon, because the company was unlikely to try to sell Inpefa outside of the U.S. on its own, according to Jefferies’ Tsai. Meanwhile, the drug fits into plans by Viatris to ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Lexicon Pharmaceuticals is selling rights to its only marketed drug outside of the U.S. and Europe amid a ...

(Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets ...